In the phase 3 PEAK trial, bezuclastinib plus sunitinib significantly improved median progression-free survival vs sunitinib alone in patients with advanced gastrointestinal stromal tumors after prior...
The FDA approved Bizengri for adults with advanced, unresectable, or metastatic NRG1 fusion-positive cholangiocarcinoma after prior systemic therapy, providing a new targeted option for an ultra-rare and...
How can primary care clinicians diagnose and manage IBS-C and chronic idiopathic constipation? Joel J. Heidelbaugh, MD, outlines evidence-based treatment options, alarm features, and when to refer to...
A double-blind, placebo-controlled cross-over trial published in BMC Gastroenterology evaluated whether 12 g/day of chicory inulin improves bowel habits, patient-reported outcomes, and gut microbiota...
In a randomized controlled trial of adults with Rome IV irritable bowel syndrome without constipation, investigators found that a Mediterranean-style low-FODMAP diet produced greater symptom improvement,...
A randomized, double-blind trial evaluated whether 4 commonly used nutritional supplements could improve symptoms or microbiota-related outcomes in adults with irritable bowel syndrome.
A post hoc analysis of the ProDeCa randomized trial found that a four-strain psychobiotic regimen added to standard analgesia reduced multidimensional pain scores in postoperative gastrointestinal cancer...
Recent research found that soft drink consumption may be linked to major depressive disorder diagnosis and increased depressive symptom severity, with significant associations observed only among women.
...
In a phase 3 trial, trastuzumab deruxtecan significantly extended overall survival compared with ramucirumab plus paclitaxel in previously treated patients, with manageable toxicity and mostly low-grade...
